Free Trial
NASDAQ:CYCC

Cyclacel Pharmaceuticals Q3 2024 Earnings Report

Cyclacel Pharmaceuticals logo
$1.45 -0.01 (-0.68%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.45 0.00 (-0.07%)
As of 05/23/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cyclacel Pharmaceuticals EPS Results

Actual EPS
-$2.88
Consensus EPS
-$8.64
Beat/Miss
Beat by +$5.76
One Year Ago EPS
N/A

Cyclacel Pharmaceuticals Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
$0.01 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Cyclacel Pharmaceuticals Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
12:00AM ET

Upcoming Earnings

Cyclacel Pharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, May 27, 2025

Cyclacel Pharmaceuticals Earnings Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
See More Cyclacel Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclacel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclacel Pharmaceuticals and other key companies, straight to your email.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals (NASDAQ:CYCC), a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

View Cyclacel Pharmaceuticals Profile

More Earnings Resources from MarketBeat